Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cidara Therapeutics (CDTX) EBT Margin: 2018-2025

Historic EBT Margin for Cidara Therapeutics (CDTX) over the last 4 years, with Mar 2025 value amounting to 21,345.45%.

  • Cidara Therapeutics' EBT Margin rose 2218585.00% to 21,345.45% in Q1 2025 from the same period last year, while for Mar 2025 it was -811.75%, marking a year-over-year decrease of 69952.00%. This contributed to the annual value of -13,356.16% for FY2024, which is 1324850.00% down from last year.
  • Latest data reveals that Cidara Therapeutics reported EBT Margin of 21,345.45% as of Q1 2025, which was up 888.35% from -2,707.62% recorded in Q2 2024.
  • Over the past 5 years, Cidara Therapeutics' EBT Margin peaked at 21,345.45% during Q1 2025, and registered a low of -2,707.62% during Q2 2024.
  • Over the past 3 years, Cidara Therapeutics' median EBT Margin value was -73.64% (recorded in 2023), while the average stood at 2,506.86%.
  • Per our database at Business Quant, Cidara Therapeutics' EBT Margin tumbled by 257,184bps in 2024 and then soared by 2,218,585bps in 2025.
  • Cidara Therapeutics' EBT Margin (Quarterly) stood at -600.11% in 2021, then spiked by 46,971bps to -130.39% in 2022, then soared by 5,675bps to -73.64% in 2023, then crashed by 257,184bps to -2,707.62% in 2024, then surged by 2,218,585bps to 21,345.45% in 2025.
  • Its EBT Margin stands at 21,345.45% for Q1 2025, versus -2,707.62% for Q2 2024 and -840.39% for Q1 2024.